Close Menu
    Tripoli WireTripoli Wire
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tripoli WireTripoli Wire
    Home » Global COVID-19 deaths have dropped by 90 percent since February
    Health

    Global COVID-19 deaths have dropped by 90 percent since February

    November 9, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Globally, COVID-19 deaths dropped nearly 90% from nine months ago, but the World Health Organization chief urged vigilance against the pandemic as variants continue to appear. Last week, just over 9,400 deaths linked to Coronavirus were reported to the WHO by Director-General Tedros Adhanom Ghebreyesus. The number of deaths worldwide exceeded 75,000 in February of this year, he said.

    Global COVID-19 deaths have dropped by 90 percent since FebruaryDespite our challenges, we have made remarkable progress, and this is definitely cause for optimism. At WHO’s Geneva headquarters, he called on governments, communities and individuals to remain vigilant. “Almost 10,000 deaths a week is 10,000 too many for a disease that can be prevented and treated.” According to the WHO chief, testing and sequencing rates remain low globally, vaccine gaps remain wide, and new variants continue to emerge.

    Related Posts

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DR Congo Ebola death toll tops 1,900 as cases rise

    August 11, 2026

    Obesity linked to 8.2% of Belgium deaths in new health report

    August 8, 2026

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Michigan reports first deaths tied to cyclospora outbreak

    August 4, 2026
    Latest News

    Wall Street rises after Treasury expands debt buybacks

    August 20, 2026

    Healthcare shares strengthen market gains
    Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026

    Total solar eclipse crosses Russian Arctic and Europe

    August 13, 2026

    International Youth Day 2026 puts youth inclusion in focus

    August 13, 2026
    © 2026 Tripoli Wire | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.